Division of Toxicology and Experimental Medicine, Central Drug Research Institute (CSIR), Lucknow, Uttar Pradesh 226031, India; Academy of Scientific and Innovative Research (AcSIR), New Delhi 110025, India.
Division of Toxicology and Experimental Medicine, Central Drug Research Institute (CSIR), Lucknow, Uttar Pradesh 226031, India.
Cytokine. 2019 Jun;118:130-143. doi: 10.1016/j.cyto.2018.03.032. Epub 2018 Apr 3.
Oncostatin M (OSM), an inflammatory cytokine belonging to the interleukin-6 (IL-6) superfamily, plays a vital role in multitude of physiological and pathological processes. Its role in breast tumor progression and metastasis to distant organs is well documented. Recent reports implicate OSM in macrophage M2 polarization, a key pro-tumoral phenomenon. M2 polarization of macrophages is believed to promote tumor progression by potentiating metastasis and angiogenesis. In the current study, we delineated the mechanism underlying OSM induced macrophage M2 polarization. The findings revealed that OSM skews macrophages towards an M2 polarized phenotype via mTOR signaling complex 2 (mTORC2). mTORC2 relays signals through two effector kinases i.e. PKC-α and Akt. Our results indicated that mTORC2 mediated M2 polarization of macrophages is not dependent on PKC-α and is primarily affected via Akt, particularly Akt1. In vivo studies conducted on 4T1/BALB/c mouse orthotropic model of breast cancer further corroborated these observations wherein i.v. reintroduction of mTORC2 abrogated monocytes into orthotropic mouse model resulted in diminished acquisition of M2 specific attributes by tumor associated macrophages. Metastasis to distant organs like lung, liver and bone was reduced as evident by decrease in formation of focal metastatic lesions in mTORC2 abrogated monocytes mice. Our study pinpoints key role of mTORC2-Akt1 axis in OSM induced macrophage polarization and suggests for possible usage of Oncostatin-M blockade and/or selective mTORC2 inhibition as a potential anti-cancer strategy particularly with reference to metastasis of breast cancer to distant organs such as lung, liver and bone.
抑瘤素 M(OSM)是白细胞介素 6(IL-6)超家族中的一种炎症细胞因子,在多种生理和病理过程中发挥着重要作用。它在乳腺癌的进展和转移到远处器官中的作用已得到充分证实。最近的报告表明,OSM 参与了巨噬细胞 M2 极化,这是一个关键的促肿瘤现象。巨噬细胞 M2 极化被认为通过促进转移和血管生成来促进肿瘤进展。在本研究中,我们阐明了 OSM 诱导巨噬细胞 M2 极化的机制。研究结果表明,OSM 通过哺乳动物雷帕霉素靶蛋白复合物 2(mTORC2)使巨噬细胞向 M2 极化表型倾斜。mTORC2 通过两种效应激酶即蛋白激酶 C-α(PKC-α)和 Akt 传递信号。我们的结果表明,mTORC2 介导的巨噬细胞 M2 极化不依赖于 PKC-α,主要通过 Akt 特别是 Akt1 来实现。在乳腺癌 4T1/BALB/c 小鼠原位模型的体内研究进一步证实了这些观察结果,即静脉内重新引入 mTORC2 使单核细胞进入原位小鼠模型后,肿瘤相关巨噬细胞获得的 M2 特异性特征减少。远处器官如肺、肝和骨的转移减少,这可通过减少 mTORC2 缺失单核细胞小鼠中焦点转移性病变的形成来证明。本研究指出了 mTORC2-Akt1 轴在 OSM 诱导的巨噬细胞极化中的关键作用,并提出了使用抑瘤素-M 阻断和/或选择性 mTORC2 抑制作为一种潜在的抗癌策略的可能性,特别是参考乳腺癌向远处器官如肺、肝和骨的转移。